Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.40 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26175331 | 0.84 | PDPK1 (0.52) | MAPK1PDPK1 | |
| SCHEMBL26176262 | 0.83 | HASPIN (0.43) | MAPTMAPK1AURKBPDPK1ROCK2 | |
| SCHEMBL26174618 | 0.81 | ROCK2 (0.49) | MAPK1AURKAAURKBINCENPTPX2 | |
| SCHEMBL26175737 | 0.78 | TGFBR1 (0.43) | AURKAAURKBROCK1 | |
| SCHEMBL26175776 | 0.77 | DYRK1A (0.37) | MAPK1AURKAAURKBPDPK1ROCK2 | |
| SCHEMBL26175678 | 0.76 | CYP2A6 (0.40) | MAPK1AURKAAURKBPDPK1ROCK2 | |
| SCHEMBL26175940 | 0.76 | DYRK1A (0.58) | MAPTMAPK1AURKBPDPK1ROCK2 | |
| SCHEMBL26175816 | 0.75 | DYRK1A (0.36) | MAPK1AURKAAURKBPDPK1ROCK2 | |
| SCHEMBL26175860 | 0.75 | DYRK1A (0.36) | MAPK1ROCK2ROCK1 | |
| SCHEMBL26174486 | 0.73 | TGFBR1 (0.53) | PDPK1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | MAPT 217/4885MAPK1 285/4885AURKA 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.